BFRI - Biofrontera Inc.
IEX Last Trade
1.04
0.044 4.221%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:13:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1.00
0.04
4.41%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.22%
1 Month
9.76%
3 Months
-18.55%
6 Months
6.32%
1 Year
-65.88%
2 Year
8.60%
Key data
Stock price
$1.04
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.72 - $3.90
52 WEEK CHANGE
-$64.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Erica L. Monaco
Region: US
Website: biofrontera.us.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biofrontera.us.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Biofrontera Inc. engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device. The RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Recent news